Plan to approach USFDA for re-inspection of key plants in next few months: Lupin

The US drug regulator, after inspecting the two sites, had expressed concerns over quality-control procedures that include handling of out-of-specification results and conducting hold-time studies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2ABZnZV
via IFTTT